Guardant Health, Inc. $GH Shares Sold by Atika Capital Management LLC

Atika Capital Management LLC lowered its stake in Guardant Health, Inc. (NASDAQ:GH) by 15.7% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 91,000 shares of the company’s stock after selling 17,000 shares during the quarter. Guardant Health comprises about 1.1% of Atika Capital Management LLC’s portfolio, making the stock its 23rd biggest holding. Atika Capital Management LLC’s holdings in Guardant Health were worth $8,406,000 as of its most recent filing with the Securities & Exchange Commission.

Other hedge funds and other institutional investors also recently modified their holdings of the company. Allworth Financial LP increased its holdings in shares of Guardant Health by 19.5% in the third quarter. Allworth Financial LP now owns 844 shares of the company’s stock valued at $53,000 after buying an additional 138 shares in the last quarter. Eastern Bank grew its position in Guardant Health by 6.9% during the fourth quarter. Eastern Bank now owns 2,160 shares of the company’s stock valued at $221,000 after purchasing an additional 139 shares in the last quarter. First Pacific Financial increased its stake in shares of Guardant Health by 33.1% in the first quarter. First Pacific Financial now owns 559 shares of the company’s stock worth $52,000 after acquiring an additional 139 shares during the last quarter. Xponance LLC raised its position in Guardant Health by 2.1% during the fourth quarter. Xponance LLC now owns 9,630 shares of the company’s stock valued at $984,000 after acquiring an additional 199 shares in the last quarter. Finally, Danske Bank A S increased its position in Guardant Health by 20.0% during the fourth quarter. Danske Bank A S now owns 1,200 shares of the company’s stock worth $123,000 after buying an additional 200 shares during the last quarter. Institutional investors own 92.60% of the company’s stock.

Guardant Health Trading Down 0.4%

GH opened at $150.20 on Friday. Guardant Health, Inc. has a 1-year low of $40.35 and a 1-year high of $174.08. The stock has a market capitalization of $19.92 billion, a PE ratio of -44.31 and a beta of 1.59. The firm has a 50-day moving average price of $138.36 and a two-hundred day moving average price of $111.70.

Insider Buying and Selling at Guardant Health

In other Guardant Health news, CEO Amirali Talasaz sold 143,028 shares of the company’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $151.54, for a total transaction of $21,674,463.12. Following the transaction, the chief executive officer owned 1,881,336 shares of the company’s stock, valued at approximately $285,097,657.44. This represents a 7.07% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CFO Michael Brian Bell sold 2,000 shares of the company’s stock in a transaction on Friday, June 5th. The stock was sold at an average price of $128.62, for a total value of $257,240.00. Following the transaction, the chief financial officer directly owned 47,509 shares in the company, valued at approximately $6,110,607.58. This represents a 4.04% decrease in their position. The SEC filing for this sale provides additional information. Insiders sold 708,565 shares of company stock valued at $90,556,597 over the last three months. Insiders own 5.60% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently weighed in on the company. Weiss Ratings reissued a “sell (d-)” rating on shares of Guardant Health in a research report on Friday, July 17th. Canaccord Genuity Group lifted their price target on Guardant Health from $135.00 to $205.00 and gave the stock a “buy” rating in a research report on Tuesday, July 14th. Piper Sandler set a $127.00 price target on Guardant Health in a report on Thursday, May 21st. Evercore reaffirmed an “outperform” rating and set a $200.00 target price on shares of Guardant Health in a research report on Monday, July 6th. Finally, Royal Bank Of Canada began coverage on shares of Guardant Health in a report on Thursday, June 11th. They set an “outperform” rating and a $185.00 price objective on the stock. One investment analyst has rated the stock with a Strong Buy rating, twenty-three have assigned a Buy rating and one has assigned a Sell rating to the company’s stock. Based on data from MarketBeat, the stock has an average rating of “Moderate Buy” and an average target price of $160.04.

Guardant Health Company Profile

Guardant Health, Inc is a precision oncology company specializing in blood-based cancer diagnostics. Founded in 2012 and headquartered in Redwood City, California, the company develops non-invasive tests that use circulating tumor DNA (ctDNA) to profile genomic alterations in patients with solid tumors. Guardant Health’s mission is to advance cancer care by providing actionable data to clinicians, pharmaceutical partners and researchers worldwide.

The company’s flagship product, Guardant360, is a next-generation sequencing (NGS) assay designed to detect mutations, copy number variations and select fusions in more than 70 cancer-related genes.